中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
11期
115-118
,共4页
诺和锐%肝功能失代偿%肝源性糖尿病
諾和銳%肝功能失代償%肝源性糖尿病
낙화예%간공능실대상%간원성당뇨병
Novorapid%Liver decompensation%Hepatogenic diabetes
目的：探讨诺和锐(门冬胰岛素注射液)短期强化治疗肝功能失代偿期肝源性糖尿病的临床疗效及安全性。方法进行为期2周的随机、开放性比较研究。将100例患者随机分为治疗组和对照组各50例。两组均采用内科常规治疗，对照组给予诺和灵30R每日早、晚餐前皮下注射方案，治疗组给予诺和锐每日早、中、晚餐前三次皮下注射强化方案。测定短期强化治疗前后两组患者空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、胰岛素(Ins)、C肽(C-P)、低血糖事件及肝功能指标(ALT、ALB及TBIL)，并计算β细胞功能(HOMA-β)和胰岛素抵抗指数(HOMA-IR)，同时比较两组治疗前后各指标的变化。结果两组治疗后FBG、2hPG、HbA1c、HOMA-IR及肝功能指标均较治疗前降低(P<0.05)，治疗组低血糖发生次数显著低于对照组(P<0.05)，且组间比较差异有统计学意义(P<0.05)。结论诺和锐短期强化治疗肝功能失代偿期肝源性糖尿病能有效降低血糖，减少低血糖事件，改善肝功能恢复状况和减轻胰岛素抵抗，具有更好的临床疗效及安全性。
目的：探討諾和銳(門鼕胰島素註射液)短期彊化治療肝功能失代償期肝源性糖尿病的臨床療效及安全性。方法進行為期2週的隨機、開放性比較研究。將100例患者隨機分為治療組和對照組各50例。兩組均採用內科常規治療，對照組給予諾和靈30R每日早、晚餐前皮下註射方案，治療組給予諾和銳每日早、中、晚餐前三次皮下註射彊化方案。測定短期彊化治療前後兩組患者空腹血糖(FBG)、餐後2 h血糖(2hPG)、糖化血紅蛋白(HbA1c)、胰島素(Ins)、C肽(C-P)、低血糖事件及肝功能指標(ALT、ALB及TBIL)，併計算β細胞功能(HOMA-β)和胰島素牴抗指數(HOMA-IR)，同時比較兩組治療前後各指標的變化。結果兩組治療後FBG、2hPG、HbA1c、HOMA-IR及肝功能指標均較治療前降低(P<0.05)，治療組低血糖髮生次數顯著低于對照組(P<0.05)，且組間比較差異有統計學意義(P<0.05)。結論諾和銳短期彊化治療肝功能失代償期肝源性糖尿病能有效降低血糖，減少低血糖事件，改善肝功能恢複狀況和減輕胰島素牴抗，具有更好的臨床療效及安全性。
목적：탐토낙화예(문동이도소주사액)단기강화치료간공능실대상기간원성당뇨병적림상료효급안전성。방법진행위기2주적수궤、개방성비교연구。장100례환자수궤분위치료조화대조조각50례。량조균채용내과상규치료，대조조급여낙화령30R매일조、만찬전피하주사방안，치료조급여낙화예매일조、중、만찬전삼차피하주사강화방안。측정단기강화치료전후량조환자공복혈당(FBG)、찬후2 h혈당(2hPG)、당화혈홍단백(HbA1c)、이도소(Ins)、C태(C-P)、저혈당사건급간공능지표(ALT、ALB급TBIL)，병계산β세포공능(HOMA-β)화이도소저항지수(HOMA-IR)，동시비교량조치료전후각지표적변화。결과량조치료후FBG、2hPG、HbA1c、HOMA-IR급간공능지표균교치료전강저(P<0.05)，치료조저혈당발생차수현저저우대조조(P<0.05)，차조간비교차이유통계학의의(P<0.05)。결론낙화예단기강화치료간공능실대상기간원성당뇨병능유효강저혈당，감소저혈당사건，개선간공능회복상황화감경이도소저항，구유경호적림상료효급안전성。
Objective To investigate the efficacy and safety of short-term intensive insulin aspart injection (Novo-rapid) therapy hepatogenic diabetes with liver decompensation patients. Mothods A two weeks randomized,open-la-bel, confrolled trial comparing Novolin 30R with short-term intensive Novorapid was performed. 100 cases were ran-domly divided into treatment group and control group,50 cases for each. The two groups were given traditional medical treatment, while the control group received Novolin 30R twice per day,the treatment group received Novorapid thrice per-day. The indicators such as FBG,2hPG,HbA1c, Ins,C-P,hypoglycemia incidence and liver function (ALT, AST, ALB and TBIL)were evaluated,β-cell function(HOMA-β)and insulin resistance index(HOMA-IR) were calculated. The changes of above indicators before and after therapy were compared between two groups. Results After the treat-ment,the FBG,2hPG,HbA1c,HOMA-IR and liver function of two groups were respectively lower than those before(P<0.05),hypoglycemia incidence of the treatment group were lower than those of the control group(P<0.05),while the differences between two groups was significant(P<0.05). Conclusion Short-term intensive Novorapid therapy for hep-atogenic diabetes with liver decompensation can reduce FBG and 2hPG,reduce the incidence of hypoglycemia, im-prove liver function,and also reduce insulin resistance. Meanwhile,the therapy is a more effective and safer therapy.
